IgniteData Advances Clinical Trial Efficiencies with Successful Deployment at Leading Cancer Center [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
to launch its innovative Archer tool for Electronic Health Record (EHR)-to-Electronic Data Capture (EDC) automation in a Phase 3 study at MSK following a successful pilot program. The deployment is based on Archer's proven ability to drive efficiencies across diverse healthcare environments, and improve clinical trial speed and accuracy. IgniteData's automation platform eliminates the need for manual data entry by securely transferring clinical data from hospital EHRs to sponsor EDCs. Through this automation, data is able to be collected faster, with fewer errors, allowing more time for researchers to focus on advancing clinical science - all while ensuring patient privacy and maintaining the highest standards of data integrity. "Our EHR-to-EDC automation technology is revolutionizing how clinical trials are conducted," said Richard Yeatman , COO of IgniteData. "By reducing manual processes and ensuring data quality, we're empowering research teams to deliver life-saving treatment
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancerBusiness Wire
AZN
Sec Filings
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- AZN's page on the SEC website